GlaxoSmithKline

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

GSK (GSK) came out with quarterly earnings of $0.90 per share, beating the Zacks Consensus Estimate of $0.85 per share. This compares to earnings of $1.10 per share a year ago.

GSK (GSK) Tops Q1 Earnings Estimates

The pharmaceutical company is vying to bring the first shot for respiratory syncytial virus to market.

GSK Earnings Beat Expectations. Race for RSV Vaccine Leads Pipeline Hopes.

GSK PLC UK:GSK on Wednesday reported net profit and sales that beat expectations but declined on-year, and backed its guidance for the full year 2023.

GSK first quarter profit dips to £1.49 billion but beat analyst forecasts

Shares in GSK PLC (LSE:GSK, NYSE:GSK) opened higher after its first-quarter revenue and profits beat expectations with the outperformance driven by the success of its Shingrix shingles vaccine. It also reaffirmed its 2023 guidance, which anticipates turnover will increase by 6-8% while operating profits will be up 10-12%.

GSK shares open higher as Q1 sales and profits beat expectations

Standard Chartered PLC (LSE:STAN) will be the first of the FTSE 100 banks to report first-quarter results, having disappointed with earnings last time, but got a modest round of applause for better-than-expected dividends and buyback news. Elsewhere in the financials sector, Man Group PLC (LSE:EMG) was given an upgrade ahead of its first-quarter update, even though performance fee expectations for the hedge fund group have fallen sharply following a difficult March.

GSK and Standard Chartered earnings on Wednesday, plus US tech giants report

AstraZeneca

GSK's first quarter should see the UK pharma in decent shape operationally says analysts though the ongoing legal battle over Zantac compensation will remain the main influence on the share price until resolved. What investors would like is some of the pipeline-driven growth long-term rival AstraZeneca has produced over the last few years.

GSK minds the gap as AstraZeneca streaks ahead

The FTSE 100's biggest company reports next week, AstraZeneca PLC (LSE:AZN) stepping up with a first-quarter trading update on Thursday, preceded by a day by its former close rival GSK PLC (LSE:GSK, NYSE:GSK).   For £187bn AZ, sales momentum remains key for investors, analysts reckon, with the company having given guidance for low-to-mid single digit total revenues growth, or low-double digits if excluding Covid medicines.

AstraZeneca results arrive with focus on drug trials, while GSK still faces Zantac overhang

Merck

Biopharmaceutical companies are getting stock price lifts this week after two big deals in the space signal that M&A appetite is ripe. On Tuesday, GSK PLC (LSE:GSK, NYSE:GSK) revealed it has paid around $2 billion for Bellus Health (TSX:BLU), a Canada-based, late-stage biopharmaceutical company which specialises in respiratory treatments.

GSK, Merck deals show appetite is ripe for biopharmaceutical M&A

Bellus Health Inc

LONDON--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) and BELLUS Health Inc. (TSX/NASDAQ: BLU) today announced that they have entered into an agreement under which GSK will acquire BELLUS, a Canada-based, late-stage biopharmaceutical company working to better the lives of patients suffering from refractory chronic cough (RCC) for US$14.75 per share of common stock in cash representing an approximate total equity value of US$2.0 billion (£1.6 billion).

GSK reaches agreement to acquire late-stage biopharmaceutical company BELLUS Health

GSK added to a series of recent takeovers Tuesday with the $2 billion acquisition of Bellus Health. But BLU stock and GSK stock diverged.

Bellus Health Soars 98% As GSK Joins Buyout Bonanza With $2 Billion Deal

Goldman Sachs

Here are some of the biggest movers on Tuesday:

Bellus Health's stock climbs on GSK deal, while Goldman Sachs is hurt by a revenue miss

GSK said Bellus' experimental cough medicine could help treat millions of people with untreatable chronic coughs and had “significant sales potential” if approved.

GSK Inks $2 Billion For Cough Medicine Biotech To Bolster Drug Pipeline

GSK PLC (LSE:GSK, NYSE:GSK) has paid around £1.6bn for Bellus Health (TSX:BLU) Inc, a Canada-based, late-stage biopharmaceutical company which specialises in respiratory treatments. The pharmaceuticals giant said the deal further strengthens specialty its medicines and respiratory pipeline with camlipixant, a highly selective P2X3 antagonist and potential best-in-class treatment for refractory chronic cough.

GSK pays £1.6bn for Canada's Bellus Health

GSK PLC said Tuesday that it has reached an agreement to buy the late-stage biopharmaceutical company Bellus Health Inc. BLU, +3.08% BLU, +2.83% for $14.75 a share in cash, representing a total equity value of around $2.0 billion.

GSK to acquire U.S.-based BELLUS Health for $14.75 per share

GSK PLC GSK, -0.49% on Monday reported positive data from its phase 3 studies for gepotidacin, its late-stage oral antibiotic for uncomplicated urinary-tract infections in female adults and teenagers.

GSK reports positive phase 3 data for UTI oral antibiotic

Moderna

Pfizer

Pfizer, GSK, and Moderna are the leaders in the race to market RSV vaccines. There's a serious unmet need with RSV causing health issues for older adults and children.

Can Pfizer Beat GSK and Moderna in This $10 Billion Market?

Income investors in search of the best dividend stocks can look overseas to U.K. pharma giant GSK. The post Best Dividend Stocks: British Pharma Giant GSK Boasts Attractive 5.2% Yield appeared first on Investor's Business Daily.

Best Dividend Stocks: British Pharma Giant GSK Boasts Attractive 5.2% Yield

GSK PLC (LSE:GSK, NYSE:GSK)'s growth outlook is being overlooked and the worst-case scenario for Zantac continues to be reflected in the share price. That's the view of Shore Capital which reiterated a buy on the pharma giant with a 1,850p share price target.

GSK growth outlook being overlooked due to Zantac concerns

Adaptimmune Therapeutics

- Adaptimmune plans to be IND-ready in 2023 with a PRAME targeted TCR T-cell therapy - - Adaptimmune and GSK will work collaboratively to ensure continuity for patients in ongoing clinical trials for lete-cel and next generation TCR T-cells targeting NY-ESO - -Adaptimmune will receive £30 million in relation to the transition of the ongoing NY-ESO clinical trials - Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - April 11, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in T-cell therapy to treat cancer, today announced entry into a transition agreement with GSK plc (LSE: GSK) (NYSE: GSK) regarding the return of rights and materials comprised within the PRAME and NY-ESO cell therapy programs. "The return of these T-cell programs to Adaptimmune bolsters our pipeline and our leadership position in the field of engineered TCR T-cells for solid tumors," said Dr. Helen Tayton-Martin, Adaptimmune's Chief Business and Strategy Officer.

Adaptimmune and GSK Have Agreed Terms for Transfer of PRAME and NY-ESO Target Programs back to Adaptimmune

Bristol-Myers

GSK's dividend yield is 3.58%, slightly higher than Bristol-Myers Squibb's 3.22%. Bristol-Myers Squibb's total debt was about $40.8 billion at the end of 2022, down $4.78 billion from the previous year, thanks to the successful integration of Celgene and MyoKardia.

GSK Vs. Bristol-Myers Squibb: Who's More Underrated By Mr. Market

Deutsche Bank repeated its ‘buy' advice and 1,700p price target for shares in GSK PLC (LSE:GSK, NYSE:GSK) in an update which assessed the news flow around its Hepatitis B research. Put simply, the latest research updates, both from the UK company and competitor Roche, make the author optimistic about GSK's potential in the Hepatitis B market.

GSK: Will vaccines do the trick? This leading bank has its say

Johnson & Johnson

Johnson & Johnson ducked out of the RSV vaccine race Wednesday, leaving Pfizer, GSK and Moderna to duke it out. The post J&J Drops Out Of A Key Race, Leaving Pfizer, GSK, Moderna To Duke It Out appeared first on Investor's Business Daily.

J&J Drops Out Of A Key Race, Leaving Pfizer, GSK, Moderna To Duke It Out

GSK PLC (LSE:GSK, NYSE:GSK) has entered into agreements with three firms to produce affordable generic versions of its long-lasting HIV prevention drug, cabotegravir, for use in lower-income countries where most new HIV cases arise. The injectable medication received approval from US regulators in late 2021.

GSK agrees HIV deal that gives lower income nations access to drug

A late-stage study data shows that GSK's Jemperli reduced disease progression risk or death by 72% for treating adult patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.

GSK's Jemperli Effective Against First-Line Endometrial Cancer

72% and 36% reduction in the risk of disease progression or death observed in the dMMR/MSI-H population and overall patient population, respectively Clinically meaningful overall survival trend observed at interim analysis Results presented in same-day presentations at ESMO Virtual Plenary and SGO Annual Meeting and simultaneously published in The New England Journal of Medicine Regulatory submissions planned for the first half of 2023 LONDON , March 27, 2023 /PRNewswire/ -- GSK plc (LSE/NYSE: GSK) today announced interim results from Part 1 of the RUBY/ENGOT-EN-6-NSGO/GOG3031 phase III trial investigating Jemperli (dostarlimab-gxly) plus standard-of-care chemotherapy (carboplatin-paclitaxel) followed by dostarlimab-gxly compared to chemotherapy plus placebo followed by placebo in adult patients with primary advanced or recurrent endometrial cancer. Hesham Abdullah, Senior Vice President, Global Head of Oncology Development, GSK said: "These positive results from the RUBY trial bring us one step closer to addressing the significant unmet needs of endometrial cancer patients and add to the growing body of evidence on dostarlimab-gxly, strengthening our belief in its potential to transform cancer treatment as a backbone immuno-oncology therapy.

Phase III RUBY clinical trial demonstrates potential of Jemperli (dostarlimab-gxly) plus chemotherapy to redefine the treatment of primary advanced or recurrent endometrial cancer versus chemotherapy alone

News for GlaxoSmithKline Stock (GSK)